- Prev close
- $243.93
- Day range
- $240.00 – $250.03
Biogen’s move looks mainly stock-specific, with a 2.2% rise alongside upbeat analyst target raises to $300 and $270, while the broader tape was only modestly firmer. The setup is constructive but not fully settled because EPS is still -46.0% YoY and the stock sits near its 52-week high.
BIIB
BIOGEN INC
As of Nov 4, 2026
62/100
Worth keeping an eye onHealth ScoreMove drivers
Biogen rose 2.2% in the session, while the S&P 500 added 0.3% and the Nasdaq 100 gained 2.2%, so the broad market does not explain the move. The bigger clue is stock-specific news: Guggenheim raised its Biogen target from $280 to $300 and HC Wainwright raised its target from $251 to $270, which lines up with BIIB outperforming same-day peers such as REGN at -4.4% and NTRA at +0.6%, even as MRNA jumped +13.1%. The primary driver is therefore stock-specific analyst-positive commentary, not a market-wide or sector-wide move.
Volatility check
This looks like ordinary but somewhat amplified volatility for a large-cap biotech, not a sign of fresh deterioration. The stock has a beta of 0.08, which usually points to muted sensitivity to the market, yet BIIB is trading at PE 44.2 and forward PE 16.5, while EPS is -46.0% YoY on a TTM basis; the PEG is 22.38, but it is not meaningful here because earnings growth is negative. Revenue is still positive at +0.3% YoY TTM and +3.4% in the latest quarter, with gross margin +74.0%, operating margin +10.9%, and net margin +8.3%, so the move is not paired with a clear fundamentals break. The main takeaway is that the business profile remains intact, but the valuation and weak EPS trend mean the shares can still swing on target changes and sentiment.
Earnings setup
The next earnings date is not available this period, so there is no confirmed print date to frame. The available consensus-style backdrop is mixed: revenue is +0.3% YoY TTM and +3.4% in the latest quarter, but EPS is -46.0% YoY TTM, with margins of gross +74.0%, operating +10.9%, and net +8.3%. There is no prior around-earnings reaction data in the facts, so the market is likely still focused on three concrete items: whether revenue growth can hold above +3.4%, whether EPS can stabilize after -46.0% YoY, and whether margins stay near the current +10.9% operating and +8.3% net levels.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track BIIB with WhyIHold
Get a plain-English explanation the next time BIOGEN INC makes a big move — so you know whether it's benign or worth your attention.